The root-cause of the stock market’s volatility and inflation does not make sense as we are reading and hearing it. At the end of this week, we will post an article about this important subject, which will also explain the reason for the long pause of the Prohost Letter. Let’s have important news... Moderna to Report Q2 2025 Financial Results Moderna, Inc. (
Important News from AbbVie AbbVie (ABBV) submitted a biological license application (BLA) to the United States’ FDA for its sensational product trenibotulinumtoxinE (TrenibotE), which reduces frown lines between the eyebrows, known as glabellar lines. The Product TrenibotE is a botulinum toxin of serotype E with short effects of a long duration for the users. The product is safer than the existing . . . This …
AbbVie FDA Approval for VYALEV for Parkinson’s Disease AbbVie (ABBV) announced that the U.S. FDA approved VYALEV™ (foscarbidopa and levodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD). From the Experts Robert A. Hauser, M.D., MBA, Professor of Neurology and Director of the Parkinson’s and Movement Disorder Center at …
AbbVie Inc Acquisition of Immunogen in the News AbbVie Inc. (ABBV) and ImmunoGen (IMGN) today announced a definitive agreement under which AbbVie will acquire . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
AbbVie Inc UBRELVY Results Published in The Lancet AbbVie Inc (ABBV) announced detailed results published in The Lancet evaluating the efficacy, safety, and tolerability of UBRELVY® (ubrogepant) 100 mg for the acute treatment of migraine when administered during the prodrome of a migraine attack. The Phase 3 study, PRODROME, showed that UBRELVY given during the prodrome (i.e., 1-6 hours before the predicted onset of headache pain) significantly reduced the …
Offsetting the Biotech Firms' Good News There is no doubt that good news is filling the media about outperformances of both development-stage small biotech firms and revenues-generating firms. This good news has been offset by inflation, hiked interest rates, that aimed at bringing down the inflation, the continued presence of COVID-19 and an unwarranted European war, which has only demonstrated the terrible impact on the …
Regenxbio Good News for wet AMD On January 10, 2022, Regenxbio Inc. (RGNX) announced the initiation of ASCENT, the second of two Phase 3 pivotal trials to evaluate the efficacy and safety of subretinal delivery of RGX-314 in patients with wet age-related macular degeneration (wet AMD). RGX-314 is being investigated as a potential one-time gene therapy for . . . This content is for paid subscribers. …
CytomX Therapeutics CytomX (CTMX) is a clinical-stage oncology-focused biopharmaceutical company developing a novel class of investigational antibody therapeutics based on the firm’s Probody® technology platform for cancer treatments. CytomX’s Probody therapeutics remain inactive until they are activated by proteases in the tumor microenvironment. Why This is Important By . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Enanta Positive Results of EPD-305 for NASH Enanta (ENTA) has positive results from the ARGON-1 Phase 2 study evaluating the safety, tolerability pharmacokinetics and efficacy of its product EPD-305 for the treatment of non-alcoholic steatohepatitis (NASH). The results met the primary endpoint of ALT reduction at week 12; in the . . . This content is for paid subscribers. Please click here to subscribe or here to …
Phase 2 clinical trial data of argenx’s (ARGX) product Efgartigimod (ARGX-113) in adult patients with primary immune thrombocytopenia (ITP) showed a favorable safety and tolerability profile. The results also demonstrated that efgartigimod caused meaningful platelet count improvements across doses and ITP patient classifications, including newly diagnosed, persistent and chronic, and correlated with a consistent reduction in IgG levels. Commenting on the news, Nicolas Leupin, Chief Medical …
AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences (NBIX), announced that the United States FDA approved Orilissa™ (elagolix) under priority review for women with moderate to severe endometriosis pain. Orilissa represents the first FDA-approved oral treatment for moderate to severe endometriosis pain in over a decade. The drug is expected to be available in U.S. retail pharmacies in early August 2018. Endometriosis is a condition where …
The Week in Review #26 IN THE BIOTECH WORLD - RESEARCH - IMPROVING CRISPR GENE EDITING The problem cited with gene editing is that the editing may stay switched on after it succeeded in reaching its goals. To prevent further unwarranted mutations, scientists from the Bath and Cardiff University have invented a switch that aims at controlling protein expression in cultured cells and mouse embryos with the …
Prohost Letter #421 PRIVATE LESSONS - Stock prices of publicly-traded biotech companies oscillate for the same reasons other industries’ stock prices swing all day long. The fluctuations are the outcome of investors’ and daily traders’ unrelenting buying and selling . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
The Week in Review #16 More Exciting Rallies in Prohost Picks - The past week and for several week fascinating outperformances have been seen for many of the Prohost Portfolio stocks. We continue to articulate that the good news is not only in the stocks’ rallies, but also in the outstanding stories behind them . . . This content is for paid subscribers. Please click here …
The Week in Review #8 Potential biotech winners inspired through COLLABORATION - When successful top-tier drug developing firms such as Amgen (AMGN) or Merck (MRK) sign strategic collaborating agreements with small development-stage biotech firms,...   . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
The Week in Review #7 A lot more happened in the past week regarding improving the treatment of cancer and of other devastating diseases. This issue contains discoveries that aim at improving breakthrough immuno-oncology treatment outcomes. Here are some of the breakthrough technologies and treatments that might improve, by-far, the management of cancer . . . This content is for paid subscribers. Please click here to …
Prohost Letter #412 Part 3 GLIOBLASTOMA - Is There Hope? Senator John McCain was diagnosed with a malignant brain tumor, glioblastoma – the most common and aggressive form of brain cancer. The cancer is so aggressive that most surgeries did not provide survival. This brain cancer affects around 3 people out of 100,000 in the U.S., with men more than women and whites more than other …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
